<code id='F6DA9D4EDA'></code><style id='F6DA9D4EDA'></style>
    • <acronym id='F6DA9D4EDA'></acronym>
      <center id='F6DA9D4EDA'><center id='F6DA9D4EDA'><tfoot id='F6DA9D4EDA'></tfoot></center><abbr id='F6DA9D4EDA'><dir id='F6DA9D4EDA'><tfoot id='F6DA9D4EDA'></tfoot><noframes id='F6DA9D4EDA'>

    • <optgroup id='F6DA9D4EDA'><strike id='F6DA9D4EDA'><sup id='F6DA9D4EDA'></sup></strike><code id='F6DA9D4EDA'></code></optgroup>
        1. <b id='F6DA9D4EDA'><label id='F6DA9D4EDA'><select id='F6DA9D4EDA'><dt id='F6DA9D4EDA'><span id='F6DA9D4EDA'></span></dt></select></label></b><u id='F6DA9D4EDA'></u>
          <i id='F6DA9D4EDA'><strike id='F6DA9D4EDA'><tt id='F6DA9D4EDA'><pre id='F6DA9D4EDA'></pre></tt></strike></i>

          
          WSS
          Boston Scientific headquarters -- Health coverage from STAT
          Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

          Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

          It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

          advertisement

          Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion